ID   PAK6_HUMAN              Reviewed;         681 AA.
AC   Q9NQU5; A8K2G2; B3KYB0; G5E9R2;
DT   19-SEP-2002, integrated into UniProtKB/Swiss-Prot.
DT   01-OCT-2000, sequence version 1.
DT   15-MAR-2017, entry version 161.
DE   RecName: Full=Serine/threonine-protein kinase PAK 6;
DE            EC=2.7.11.1;
DE   AltName: Full=PAK-5;
DE   AltName: Full=p21-activated kinase 6;
DE            Short=PAK-6;
GN   Name=PAK6; Synonyms=PAK5;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), TISSUE SPECIFICITY,
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH AR.
RX   PubMed=11278661; DOI=10.1074/jbc.M010311200;
RA   Yang F., Li X., Sharma M., Zarnegar M., Lim B., Sun Z.;
RT   "Androgen receptor specifically interacts with a novel p21-activated
RT   kinase, PAK6.";
RL   J. Biol. Chem. 276:15345-15353(2001).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1).
RA   Wagner T., Puls A., Frischauf A.M., Hall A.;
RT   "Pak5, a new member of the p21-activated kinase family, affects Cdc42
RT   signalling to the actin cytoskeleton.";
RL   Submitted (FEB-1999) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORMS 1 AND 2).
RC   TISSUE=Amygdala, Brain, and Thalamus;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R.,
RA   Fahey J., Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G.,
RA   Johnson E., Jones C., Kamat A., Kaur A., Locke D.P., Madan A.,
RA   Munson G., Jaffe D.B., Lui A., Macdonald P., Mauceli E., Naylor J.W.,
RA   Nesbitt R., Nicol R., O'Leary S.B., Ratcliffe A., Rounsley S., She X.,
RA   Sneddon K.M.B., Stewart S., Sougnez C., Stone S.M., Topham K.,
RA   Vincent D., Wang S., Zimmer A.R., Birren B.W., Hood L., Lander E.S.,
RA   Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human
RT   chromosome 15.";
RL   Nature 440:671-675(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   TISSUE SPECIFICITY, SUBCELLULAR LOCATION, AND INTERACTION WITH AR AND
RP   ESR1.
RX   PubMed=11773441; DOI=10.1210/mend.16.1.0753;
RA   Lee S.R., Ramos S.M., Ko A., Masiello D., Swanson K.D., Lu M.L.,
RA   Balk S.P.;
RT   "AR and ER interaction with a p21-activated kinase (PAK6).";
RL   Mol. Endocrinol. 16:85-99(2002).
RN   [8]
RP   FUNCTION IN PHOSPHORYLATION OF AR.
RX   PubMed=14573606; DOI=10.1074/jbc.M311145200;
RA   Schrantz N., da Silva Correia J., Fowler B., Ge Q., Sun Z.,
RA   Bokoch G.M.;
RT   "Mechanism of p21-activated kinase 6-mediated inhibition of androgen
RT   receptor signaling.";
RL   J. Biol. Chem. 279:1922-1931(2004).
RN   [9]
RP   PHOSPHORYLATION BY MAP2K6, AUTOPHOSPHORYLATION, AND MUTAGENESIS OF
RP   SER-165; SER-560 AND TYR-566.
RX   PubMed=15550393; DOI=10.1074/jbc.M406701200;
RA   Kaur R., Liu X., Gjoerup O., Zhang A., Yuan X., Balk S.P.,
RA   Schneider M.C., Lu M.L.;
RT   "Activation of p21-activated kinase 6 by MAP kinase kinase 6 and p38
RT   MAP kinase.";
RL   J. Biol. Chem. 280:3323-3330(2005).
RN   [10]
RP   INTERACTION WITH IQGAP1 AND PPM1B.
RX   PubMed=18642328; DOI=10.1002/pros.20787;
RA   Kaur R., Yuan X., Lu M.L., Balk S.P.;
RT   "Increased PAK6 expression in prostate cancer and identification of
RT   PAK6 associated proteins.";
RL   Prostate 68:1510-1516(2008).
RN   [11]
RP   FUNCTION.
RX   PubMed=20054820; DOI=10.1002/pros.21114;
RA   Zhang M., Siedow M., Saia G., Chakravarti A.;
RT   "Inhibition of p21-activated kinase 6 (PAK6) increases
RT   radiosensitivity of prostate cancer cells.";
RL   Prostate 70:807-816(2010).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (1.6 ANGSTROMS) OF 383-681, AND PHOSPHORYLATION
RP   AT SER-560.
RA   Filippakopoulos P., Berridge G., Bray J., Burgess N., Colebrook S.,
RA   Das S., Eswaran J., Gileadi O., Papagrigoriou E., Savitsky P.,
RA   Smee C., Turnbull A., Sundstrom M., Arrowsmith C., Weigelt J.,
RA   Edwards A., Von Delft F., Knapp S.;
RT   "Crystal structure of the human p21-activated kinase 6.";
RL   Submitted (FEB-2006) to the EMBL/GenBank/DDBJ databases.
RN   [13]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS) OF 11-45 IN COMPLEX WITH CDC42.
RG   Structural genomics consortium (SGC);
RT   "The crystal structure of human CDC42 in complex with the CRIB domain
RT   of human p21-activated kinase 6 (PAK6).";
RL   Submitted (JAN-2007) to the PDB data bank.
RN   [14]
RP   VARIANT [LARGE SCALE ANALYSIS] HIS-3.
RX   PubMed=16959974; DOI=10.1126/science.1133427;
RA   Sjoeblom T., Jones S., Wood L.D., Parsons D.W., Lin J., Barber T.D.,
RA   Mandelker D., Leary R.J., Ptak J., Silliman N., Szabo S.,
RA   Buckhaults P., Farrell C., Meeh P., Markowitz S.D., Willis J.,
RA   Dawson D., Willson J.K.V., Gazdar A.F., Hartigan J., Wu L., Liu C.,
RA   Parmigiani G., Park B.H., Bachman K.E., Papadopoulos N.,
RA   Vogelstein B., Kinzler K.W., Velculescu V.E.;
RT   "The consensus coding sequences of human breast and colorectal
RT   cancers.";
RL   Science 314:268-274(2006).
RN   [15]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-76; LYS-184; GLU-205; THR-208;
RP   MET-210; ARG-215; LEU-337; VAL-376 AND ARG-514.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in the
CC       regulation of gene transcription. The kinase activity is induced
CC       by various effectors including AR or MAP2K6/MAPKK6. Phosphorylates
CC       the DNA-binding domain of androgen receptor/AR and thereby
CC       inhibits AR-mediated transcription. Inhibits also ESR1-mediated
CC       transcription. May play a role in cytoskeleton regulation by
CC       interacting with IQGAP1. May protect cells from apoptosis through
CC       phosphorylation of BAD. {ECO:0000269|PubMed:14573606,
CC       ECO:0000269|PubMed:20054820}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound
CC       CDC42/p21 and RAC1 (By similarity). Interacts with the androgen
CC       receptor AR and the estrogen receptor ESR1. Interacts with IQGAP1
CC       and PPM1B. {ECO:0000250, ECO:0000269|PubMed:11278661,
CC       ECO:0000269|PubMed:11773441, ECO:0000269|PubMed:18642328,
CC       ECO:0000269|Ref.13}.
CC   -!- INTERACTION:
CC       Q5S007:LRRK2; NbExp=2; IntAct=EBI-1053685, EBI-5323863;
CC       Q9H4E5:RHOJ; NbExp=3; IntAct=EBI-1053685, EBI-6285694;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm. Nucleus. Note=Cotranslocates into
CC       nucleus with AR in response to androgen induction.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q9NQU5-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q9NQU5-2; Sequence=VSP_056733;
CC   -!- TISSUE SPECIFICITY: Selectively expressed in brain and testis,
CC       with lower levels in multiple tissues including prostate and
CC       breast. {ECO:0000269|PubMed:11278661,
CC       ECO:0000269|PubMed:11773441}.
CC   -!- PTM: Autophosphorylated. Phosphorylated by MAP2K6//MAPKK6, leading
CC       to PAK6 activation. {ECO:0000269|PubMed:15550393,
CC       ECO:0000269|Ref.12}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF276893; AAF82800.1; -; mRNA.
DR   EMBL; AJ236915; CAC18720.1; -; mRNA.
DR   EMBL; AK131522; BAG54772.1; -; mRNA.
DR   EMBL; AK290227; BAF82916.1; -; mRNA.
DR   EMBL; AK315813; BAF98704.1; -; mRNA.
DR   EMBL; AK315817; BAF98708.1; -; mRNA.
DR   EMBL; AC020658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC025429; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471125; EAW92395.1; -; Genomic_DNA.
DR   EMBL; CH471125; EAW92401.1; -; Genomic_DNA.
DR   EMBL; BC035596; AAH35596.1; -; mRNA.
DR   CCDS; CCDS10054.1; -. [Q9NQU5-1]
DR   CCDS; CCDS61590.1; -. [Q9NQU5-2]
DR   RefSeq; NP_001122100.1; NM_001128628.2. [Q9NQU5-1]
DR   RefSeq; NP_001122101.1; NM_001128629.2. [Q9NQU5-1]
DR   RefSeq; NP_001263646.1; NM_001276717.1. [Q9NQU5-1]
DR   RefSeq; NP_001263647.1; NM_001276718.1. [Q9NQU5-2]
DR   RefSeq; NP_064553.1; NM_020168.5. [Q9NQU5-1]
DR   UniGene; Hs.732375; -.
DR   UniGene; Hs.745440; -.
DR   PDB; 2C30; X-ray; 1.60 A; A=383-681.
DR   PDB; 2ODB; X-ray; 2.40 A; B=11-45.
DR   PDB; 4KS7; X-ray; 1.40 A; A=385-674.
DR   PDB; 4KS8; X-ray; 1.95 A; A=385-674.
DR   PDBsum; 2C30; -.
DR   PDBsum; 2ODB; -.
DR   PDBsum; 4KS7; -.
DR   PDBsum; 4KS8; -.
DR   ProteinModelPortal; Q9NQU5; -.
DR   SMR; Q9NQU5; -.
DR   BioGrid; 121251; 21.
DR   IntAct; Q9NQU5; 14.
DR   MINT; MINT-8247581; -.
DR   STRING; 9606.ENSP00000260404; -.
DR   BindingDB; Q9NQU5; -.
DR   ChEMBL; CHEMBL4311; -.
DR   GuidetoPHARMACOLOGY; 2137; -.
DR   iPTMnet; Q9NQU5; -.
DR   PhosphoSitePlus; Q9NQU5; -.
DR   DMDM; 23396789; -.
DR   EPD; Q9NQU5; -.
DR   MaxQB; Q9NQU5; -.
DR   PaxDb; Q9NQU5; -.
DR   PeptideAtlas; Q9NQU5; -.
DR   PRIDE; Q9NQU5; -.
DR   DNASU; 56924; -.
DR   Ensembl; ENST00000260404; ENSP00000260404; ENSG00000137843. [Q9NQU5-1]
DR   Ensembl; ENST00000455577; ENSP00000409465; ENSG00000137843. [Q9NQU5-2]
DR   Ensembl; ENST00000542403; ENSP00000439597; ENSG00000137843. [Q9NQU5-1]
DR   Ensembl; ENST00000560346; ENSP00000453858; ENSG00000137843. [Q9NQU5-1]
DR   GeneID; 106821730; -.
DR   GeneID; 56924; -.
DR   KEGG; hsa:106821730; -.
DR   KEGG; hsa:56924; -.
DR   UCSC; uc001zky.5; human. [Q9NQU5-1]
DR   CTD; 106821730; -.
DR   CTD; 56924; -.
DR   DisGeNET; 56924; -.
DR   GeneCards; PAK6; -.
DR   HGNC; HGNC:16061; PAK6.
DR   HPA; HPA031124; -.
DR   MIM; 608110; gene.
DR   neXtProt; NX_Q9NQU5; -.
DR   OpenTargets; ENSG00000137843; -.
DR   OpenTargets; ENSG00000259288; -.
DR   PharmGKB; PA32921; -.
DR   eggNOG; KOG0578; Eukaryota.
DR   eggNOG; ENOG410XP4K; LUCA.
DR   GeneTree; ENSGT00860000133680; -.
DR   HOGENOM; HOG000234205; -.
DR   HOVERGEN; HBG108518; -.
DR   InParanoid; Q9NQU5; -.
DR   KO; K05735; -.
DR   OMA; HSGRHVA; -.
DR   OrthoDB; EOG091G0OT5; -.
DR   PhylomeDB; Q9NQU5; -.
DR   TreeFam; TF105352; -.
DR   Reactome; R-HSA-428540; Activation of Rac.
DR   SignaLink; Q9NQU5; -.
DR   SIGNOR; Q9NQU5; -.
DR   EvolutionaryTrace; Q9NQU5; -.
DR   GeneWiki; PAK6; -.
DR   GenomeRNAi; 56924; -.
DR   PRO; PR:Q9NQU5; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   Bgee; ENSG00000137843; -.
DR   CleanEx; HS_PAK6; -.
DR   ExpressionAtlas; Q9NQU5; baseline and differential.
DR   Genevisible; Q9NQU5; HS.
DR   GO; GO:0030054; C:cell junction; IDA:HPA.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0001650; C:fibrillar center; IDA:HPA.
DR   GO; GO:0005634; C:nucleus; IDA:HPA.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0045296; F:cadherin binding; IDA:BHF-UCL.
DR   GO; GO:0004702; F:signal transducer, downstream of receptor, with serine/threonine kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; TAS:UniProtKB.
DR   GO; GO:0007010; P:cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:0006355; P:regulation of transcription, DNA-templated; TAS:UniProtKB.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; ATP-binding; Complete proteome;
KW   Cytoplasm; Kinase; Nucleotide-binding; Nucleus; Phosphoprotein;
KW   Polymorphism; Reference proteome; Serine/threonine-protein kinase;
KW   Transferase.
FT   CHAIN         1    681       Serine/threonine-protein kinase PAK 6.
FT                                /FTId=PRO_0000086476.
FT   DOMAIN       12     25       CRIB. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00057}.
FT   DOMAIN      407    658       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   NP_BIND     413    421       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION       26    406       Linker.
FT   ACT_SITE    526    526       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   BINDING     436    436       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES     560    560       Phosphoserine; by autocatalysis.
FT                                {ECO:0000250}.
FT   VAR_SEQ     583    627       Missing (in isoform 2).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_056733.
FT   VARIANT       3      3       R -> H (in a colorectal cancer sample;
FT                                somatic mutation; dbSNP:rs201346085).
FT                                {ECO:0000269|PubMed:16959974}.
FT                                /FTId=VAR_035631.
FT   VARIANT      76     76       M -> V (in dbSNP:rs2412504).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019993.
FT   VARIANT     103    103       R -> C (in dbSNP:rs36081263).
FT                                /FTId=VAR_051655.
FT   VARIANT     151    151       T -> I (in dbSNP:rs35593179).
FT                                /FTId=VAR_051656.
FT   VARIANT     184    184       E -> K (in dbSNP:rs56349744).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040972.
FT   VARIANT     205    205       G -> E (in dbSNP:rs55920845).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040973.
FT   VARIANT     208    208       P -> T (in dbSNP:rs35501648).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040974.
FT   VARIANT     210    210       T -> M (in dbSNP:rs34869667).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040975.
FT   VARIANT     215    215       H -> R (in dbSNP:rs3743135).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019994.
FT   VARIANT     337    337       P -> L (in dbSNP:rs3743137).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_019995.
FT   VARIANT     376    376       A -> V (in dbSNP:rs55806501).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040976.
FT   VARIANT     475    475       E -> K (in dbSNP:rs34445577).
FT                                /FTId=VAR_051657.
FT   VARIANT     514    514       L -> R (in a lung small cell carcinoma
FT                                sample; somatic mutation).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_040977.
FT   MUTAGEN     165    165       S->A: Almost complete loss of PAK6
FT                                activation by MAP2K6/MAPKK6; when
FT                                associated with F-566.
FT                                {ECO:0000269|PubMed:15550393}.
FT   MUTAGEN     560    560       S->A: Complete loss of PAK6 activation by
FT                                MAP2K6/MAPKK6; when associated with A-
FT                                165. {ECO:0000269|PubMed:15550393}.
FT   MUTAGEN     566    566       Y->F: Complete loss of PAK6 activation by
FT                                MAP2K6/MAPKK6; when associated with A-
FT                                165. {ECO:0000269|PubMed:15550393}.
FT   CONFLICT     60     60       T -> A (in Ref. 3; BAG54772).
FT                                {ECO:0000305}.
FT   CONFLICT    381    381       D -> G (in Ref. 3; BAG54772).
FT                                {ECO:0000305}.
FT   STRAND       16     27       {ECO:0000244|PDB:2ODB}.
FT   TURN         28     31       {ECO:0000244|PDB:2ODB}.
FT   STRAND       32     35       {ECO:0000244|PDB:2ODB}.
FT   HELIX        38     44       {ECO:0000244|PDB:2ODB}.
FT   HELIX       387    395       {ECO:0000244|PDB:4KS7}.
FT   HELIX       404    406       {ECO:0000244|PDB:4KS7}.
FT   STRAND      407    416       {ECO:0000244|PDB:4KS7}.
FT   STRAND      419    426       {ECO:0000244|PDB:4KS7}.
FT   TURN        427    429       {ECO:0000244|PDB:4KS7}.
FT   STRAND      432    439       {ECO:0000244|PDB:4KS7}.
FT   TURN        440    442       {ECO:0000244|PDB:2C30}.
FT   HELIX       446    448       {ECO:0000244|PDB:4KS7}.
FT   HELIX       449    458       {ECO:0000244|PDB:4KS7}.
FT   STRAND      467    473       {ECO:0000244|PDB:4KS7}.
FT   STRAND      476    481       {ECO:0000244|PDB:4KS7}.
FT   HELIX       489    493       {ECO:0000244|PDB:4KS7}.
FT   HELIX       500    519       {ECO:0000244|PDB:4KS7}.
FT   HELIX       529    531       {ECO:0000244|PDB:4KS7}.
FT   STRAND      532    534       {ECO:0000244|PDB:4KS7}.
FT   STRAND      540    542       {ECO:0000244|PDB:4KS7}.
FT   HELIX       545    547       {ECO:0000244|PDB:4KS7}.
FT   STRAND      553    555       {ECO:0000244|PDB:4KS7}.
FT   HELIX       565    567       {ECO:0000244|PDB:4KS7}.
FT   HELIX       570    573       {ECO:0000244|PDB:4KS7}.
FT   HELIX       581    596       {ECO:0000244|PDB:4KS7}.
FT   TURN        600    603       {ECO:0000244|PDB:4KS7}.
FT   HELIX       606    615       {ECO:0000244|PDB:4KS7}.
FT   HELIX       624    626       {ECO:0000244|PDB:4KS7}.
FT   HELIX       629    638       {ECO:0000244|PDB:4KS7}.
FT   TURN        643    645       {ECO:0000244|PDB:4KS7}.
FT   HELIX       649    653       {ECO:0000244|PDB:4KS7}.
FT   HELIX       656    660       {ECO:0000244|PDB:4KS7}.
FT   HELIX       664    670       {ECO:0000244|PDB:4KS7}.
SQ   SEQUENCE   681 AA;  74869 MW;  F20A4FA257649BB9 CRC64;
     MFRKKKKKRP EISAPQNFQH RVHTSFDPKE GKFVGLPPQW QNILDTLRRP KPVVDPSRIT
     RVQLQPMKTV VRGSAMPVDG YISGLLNDIQ KLSVISSNTL RGRSPTSRRR AQSLGLLGDE
     HWATDPDMYL QSPQSERTDP HGLYLSCNGG TPAGHKQMPW PEPQSPRVLP NGLAAKAQSL
     GPAEFQGASQ RCLQLGACLQ SSPPGASPPT GTNRHGMKAA KHGSEEARPQ SCLVGSATGR
     PGGEGSPSPK TRESSLKRRL FRSMFLSTAA TAPPSSSKPG PPPQSKPNSS FRPPQKDNPP
     SLVAKAQSLP SDQPVGTFSP LTTSDTSSPQ KSLRTAPATG QLPGRSSPAG SPRTWHAQIS
     TSNLYLPQDP TVAKGALAGE DTGVVTHEQF KAALRMVVDQ GDPRLLLDSY VKIGEGSTGI
     VCLAREKHSG RQVAVKMMDL RKQQRRELLF NEVVIMRDYQ HFNVVEMYKS YLVGEELWVL
     MEFLQGGALT DIVSQVRLNE EQIATVCEAV LQALAYLHAQ GVIHRDIKSD SILLTLDGRV
     KLSDFGFCAQ ISKDVPKRKS LVGTPYWMAP EVISRSLYAT EVDIWSLGIM VIEMVDGEPP
     YFSDSPVQAM KRLRDSPPPK LKNSHKVSPV LRDFLERMLV RDPQERATAQ ELLDHPFLLQ
     TGLPECLVPL IQLYRKQTST C
//
